Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2026-04-14 Governance Information
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2026年度独立董事述职报告（肖永欢）
Governance Information Classification · 88% confidence The document is a detailed "Independent Director’s Work Report" (独立董事述职报告) covering board meeting attendance, committee activities, duties performed, and governance oversight by the independent director for the year. It is not announcing management changes, financial results, dividends, or capital transactions, nor is it the annual report itself. Instead, it pertains to corporate governance practices and board structure oversight. This aligns with the definition of Governance Information (CGR).
2026-04-14 Chinese
2025年度董事会工作报告
Governance Information Classification · 88% confidence The document is the 2025年度董事会工作报告 (“Board of Directors Work Report”) of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It provides a detailed account of the board’s activities, governance structures, board and shareholder meetings, internal control systems, committee work, director performance, and future board plans. It is not an earnings release, annual report, or management change notice, but rather a governance-focused report on internal rules, board operations, and oversight practices. This aligns with the Governance Information category (CGR).
2026-04-14 Chinese
2025年年度权益分派预案公告
Notice of Dividend Amount Classification · 90% confidence The document is titled "2025年年度权益分派预案公告" and provides detailed information on the company’s proposed dividend distribution plan (cash dividend per share, total amount, legal basis, board and audit committee approvals, corporate charter provisions, etc.). It is an announcement of the dividend amount and distribution details, matching the definition of a Notice of Dividend Amount (Code: DIV). It is not merely a link or notice to publish a report, nor is it a full annual or interim report.
2026-04-14 Chinese
2025年度审计报告
Audit Report / Information Classification · 95% confidence The document is the standalone audit report for the fiscal year ending December 31, 2025 (titled “2025 年度审计报告”), containing the auditor’s opinion, basis of opinion, key audit matters, and the full set of audited consolidated and parent company financial statements with notes. This aligns with the “Audit Report / Information” category (Code: AR). FY 2025
2026-04-14 Chinese
非经营性资金占用及其他关联资金往来情况的专项审核说明
Audit Report / Information Classification · 95% confidence The document is a standalone special audit report issued by Zhonghui CPA firm on non-operating fund occupation and related-party transactions for Jiangxi Xinganjiang Pharma for the 2025 fiscal year. It contains audit scope, CPA responsibilities, and a review opinion, but is not a full annual report or earnings release. This fits the definition of an Audit Report / Information (AR). FY 2025
2026-04-14 Chinese
2025年度独立董事述职报告（程谋）
Governance Information Classification · 74% confidence The document is a comprehensive annual ‘述职报告’ (performance report) by an independent director of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. for the 2025 fiscal year. It outlines his duties, meeting attendance, committee work, independent opinions on major corporate actions, communication with auditors and shareholders, and other governance activities. This is not an earnings release, audit report, capital update, or management’s discussion of financial results; rather it is a corporate governance disclosure focused on board structure, director responsibilities, compliance with listing rules, and protection of minority investors. Thus, it falls under Governance Information (Code: CGR).
2026-04-14 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.